Background: Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.
Introduction
Adherence to HAART is crucial for maintaining the suppression of HIV replication, which is the paramount factor affecting long-term prognosis of HIV-infected individuals.
1 Adherence assessment has not been standardized so far; self-report, medication event monitoring systems (MEMS) and pharmacy refill records are indirect methods used to measure patient compliance with medications. Therapeutic drug monitoring (TDM) is an objective measure of drug plasma concentrations and is usually performed in selected patients according to national and international guidelines. 3 The use of TDM to evaluate adherence to treatment has been described in several studies. 4 While it may confirm incomplete adherence it is only partially useful in estimating the actual degree of compliance and persistence regarding drug intake. 5 A 'white coat effect', i.e. the possibility of a better adherence shortly before a scheduled visit, has been described. 6 Boosted PI plasma concentrations are adequate in the majority of patients and resistance-associated mutations are rarely selected at failure. Besides lopinavir/ritonavir, all other boosted PIs require the simultaneous intake of the PI and low-dose ritonavir tablets; selective non-adherence to ritonavir has been reported in approximately 8% of patients. 7 The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and commonly used boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.
Methods
Two retrospective studies were conducted between 2008 and 2015; a TDM registry analysis and a retrospective evaluation of immunovirological data of patients included in the TDM registry for whom clinical information was available ('follow-up'). Written patient consent was V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
obtained at each blood withdrawal; the ASL TO2 Ethics Committee approved the protocol.
Adult HIV-positive patients were included the TDM registry study if a measurement of their plasma concentration was included in the TDM registry of the University of Torino (Torino, Italy) and if they were receiving boosted PIs. Exclusion criteria were as follows: concomitant treatment with known interacting drugs, pregnancy, hepatic impairment and renal impairment. Plasma ritonavir and PI concentrations were measured by validated HPLC/MS-MS methods with limits of detection of 9.8 ng/mL ritonavir, 58.6 ng/mL lopinavir, 11.7 ng/mL atazanavir and 19.5 ng/mL darunavir. 8 For atazanavir samples withdrawn 4-21 h after dose intake, trough values were calculated using the formula: calculated C trough " concentration/ {2^[(24-time after dose)/half-life]}.
By relying on previous findings showing that boosted ritonavir concentrations are expected to be measurable at the end of the dosing interval, patients were grouped according to the drug plasma levels detected and stratified into three adherence groups: detectable ritonavir and PI (adherent), detectable PI with undetectable ritonavir (partially non-adherent) and both PI and ritonavir undetectable (non-adherent).
9,10
The follow-up analysis was performed at the outpatient clinic of the Amedeo di Savoia Hospital (Torino, Italy) and included patients in the TDM registry for whom clinical and virological details were available. A genotypic susceptibility score (GSS) was calculated using the Stanford algorithm on cumulative genotypes. Virological failure was defined as two consecutive viral load determinations above 50 copies/mL (at least 7 days apart) during the following 12 months.
Non-parametric tests (Mann-Whitney, Kruskal-Wallis and Fisher's exact test) were used to compare categorical and continuous variables. All factors with a P value ,0.10 at bivariate analysis were included in a binary logistic regression multivariate analysis.
Results
The study included 2468 samples collected from 723 patients (median 3 samples/patient). Patients were mostly male (68.1%); median (IQR) age and BMI were 43.5 years (38.1-50.3) and 23 kg/m 2 (21-24.9), respectively. The plasma concentration results are shown in Table 1 . Following the TDM-based definition of adherence, 87 samples (3.5%, 74 patients) and 68 samples (2.8%, 52 patients) were deemed partially non-adherent and non-adherent, respectively. Samples from patients on atazanavir/ritonavir had the highest chance of falling in the partially non-adherent category (7.9%), followed by those on darunavir/ ritonavir (2% twice daily and 1.9% once daily) and lopinavir/ ritonavir (1.5%; P , 0.001).
Two hundred and ninety patients were included in the followup study; subjects were mostly male (64.1%); median (IQR) age and BMI were 40 years (44-51) and 23.4 kg/m 2 (20. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .2), respectively. Baseline and nadir CD4! T lymphocyte cell counts were 398/lL (231-556) and 171/lL (45-225), respectively; baseline viral load was ,50 copies/mL in 172 patients (59.3%) and in those with detectable HIV RNA it was 2.7 log 10 copies/mL (2.2-4.3). Patients had been on the baseline treatment for 6 months (2-12) and previous failure of NNRTI-or PI-containing regimens was observed in 73/232 (31.5%) and 71/236 (30.1%) patients, respectively. According to the plasma levels of the drugs, 209 subjects (72.1%) were classified as adherent, while 48 (16.6%) and 33 (11.4%) were classified as partially non-adherent and non-adherent, respectively. Patients on once-daily darunavir/ritonavir had the highest prevalence in the adherent group (88.9%), followed by those on twice-daily darunavir/ritonavir, lopinavir/ritonavir and atazanavir/ ritonavir (82.9%, 74% and 57.4%, respectively). During 48 weeks of follow-up 217 (74.8%) subjects obtained and maintained an HIV RNA below 50 copies/mL. Patients in the adherent group had a higher chance of controlling HIV RNA at 48 weeks (167/204, 81.9%) as compared with those in the partially non-adherent and non-adherent groups (33/46, 71.7% and 17/32, 53.1%; P " 0.001) ( Table 2) .
Based on stepwise multivariate regression analysis (including also PI group, number of pills, age and gender), the following variables were independent predictors of 48 week HIV RNA .50 copies/mL: baseline HIV RNA .50 copies/mL [P , 0.001; adjusted OR (aOR) " 4.3; 95% CI " 2.1-9.1], GSS 2 (P " 0.001; aOR " 5.1; 95% CI " 2.1-12.4), a 100 cells/lL decrease in nadir CD4 cell count (P " 0.003; aOR " 0.5; 95% CI " 0.3-0.8) and not being in the TDM-defined adherent group (P " 0.029; aOR " 1.7; 95% CI " 1.1-2.9).
Discussion
We observed that TDM-defined suboptimal adherence to PI-based antiretroviral regimens could be found in approximately 6% of patients and that those with undetectable levels have a higher risk of incomplete viral control in the follow-up.
We should first acknowledge the limitations of such an analysis, including the potential bias by indication (unreported adherence issues), the retrospective nature of the studies and the heterogeneous features of the patients included in the follow-up study.
By measuring the plasma concentrations of the most commonly used boosted PIs in patients not fulfilling the criteria for TDM according to recommended guidelines, we aimed to assess the Calcagno et al.
prevalence of correct adherence to those antiretroviral regimens and the association between adherence and the 48 week risk of virological failure. We identified three groups of patients according to the C trough of PIs and ritonavir, assuming this value could be a marker of adherence for the 3-7 days before the observation. The three groups describe three different patterns of recent adherence: detectable PI and undetectable ritonavir mean either the last doses of both PI and ritonavir have been missed or selective non-adherence to ritonavir, while both PI and ritonavir undetectable indicates that more than one PI and ritonavir doses have been missed. While this categorization might be arbitrary it was, however, based on the estimated half-life of PIs after cessation of their administration as described by Boffito et al. 9,10 A GSS .2, a higher nadir CD4 cell count and a baseline controlled viral load were associated with virological suppression, showing how an appropriate choice of antiretroviral regimen based on the virus and host features plays a key role in the long-term control of viral replication.
Adherence represents one main factor in obtaining virological suppression and to achieve the full benefits of ART. Ensuring adherence is a complex process involving the patient's behaviour and beliefs, mood and tolerability, as well as the ability of physicians to guide the patient in maintaining a high level of adherence to the prescribed antiretroviral regimen. The importance of adherence is highlighted by the linear association between virological failure and missed drug doses, as well as between non-adherence and risk of progression of the disease and death; however, with ongoing viral control less rigorous adherence might be sufficient to suppress viral replication.
11 Several previously published studies showed the effectiveness of a combination of methods as the best way to detect non-adherence; for instance Yasuda et al. 12 found that random PI concentration values were independent predictors of virological response. Furthermore, untimed plasma drug concentration and pill intake self-report has been recognized as a tool to identify patients at risk of virological rebound. [13] [14] [15] On the other hand, there is evidence that reducing pill burden and frequency of administration may be beneficial and single-tablet regimens are now available in well-resourced countries. 16 PI-based single-tablet regimens are still under investigation and the number of pills in a PI-based regimen may be predictive of virological failure even in the context of low-level viraemia. 17 These findings might be relevant given the recent approval of cobicistat co-formulated with the PIs atazanavir and darunavir; this would reduce the number of pills, avoid selective nonadherence to ritonavir and, finally, increase patients' adherence to PI-based regimens. Clinical trials comparing cobicistat-boosted PIs with ritonavir-boosted PIs showed good results. 18, 19 In conclusion, the measurement of PI and ritonavir plasma levels can uncover incomplete compliance with medications and thus TDM may represent a useful tool for identifying patients in need of adherence-promoting interventions in order to maintain future therapeutic options.
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